This post was originally published on this site
As per the modified supply agreement with the government, Lilly will provide an additional 150,000 doses of bebtelovimab for about $275 million. The drug has also shown effectiveness against the Omicron variant.
The FDA authorized the drug earlier this year for emergency use in patients with mild-to-moderate COVID-19 who are at high risk of progression to severe disease, including hospitalization or death.
Lilly said bebtelovimab retains effectiveness against Omicron as well as its fast-spreading BA.4 and BA.5 subvariants, which now make up more than 50% of COVID cases in the United States.
Lilly said delivery will begin immediately and U.S. has an option to buy additional 350,000 doses till September 14.
